SAN CLEMENTE, Calif., March 7, 2013 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI) today announced that its family of needlefree intravenous (IV) connectors was chosen by U.S. healthcare providers more than twice as often as any other connector technology according to newly released full year 2012 market intelligence data from independent research company Global Healthcare Exchange (GHX).1
Each of ICU Medical's needlefree connectors—including the NeutronTM catheter patency device, the MicroClave® Clear neutral displacement needlefree connector, and the NanoClaveTM low profile needlefree connector—incorporates the company's foundational split septum and internal blunt cannula technology. Together with the original Clave® and MicroClave® connectors, ICU Medical's technology accounted for 43% of the needlefree connector market in the United States in 2012. The next leading technology, CareFusion's MaxPlus®/MaxPlus® Clear, reportedly accounted for only 21% of the market.
The design of a needlefree IV connector plays a substantial role in the ability to limit hospital-acquired bloodstream infections (HA-BSI).2 The neutral displacement straight fluid path design, split-septum and minimal deadspace of ICU Medical's connector technology work together to help minimize blood reflux into the tip of the catheter upon connection or disconnection of the luer and has been clinically proven to provide an effective microbial barrier against bacteria transfer and contamination.3,4 Additional technology integrated into the Neutron allows that device to further reduce blood reflux into the catheter and has been shown to help reduce catheter occlusions by as much as 50% as a result.5
"As the company that created the market for safe IV connectors with the invention of the original ClickLock in 1984, we're proud that clinicians choose our technology more than twice as often as any other," explained ICU Medical CEO Dr. George Lopez . "And as the inventor of these technologies, it's gratifying to see so many patients kept safe as a result of our work."